SecBot SecBot

PDSB drug pipeline

PDS Biotechnology Corp · 3 rated drugs
$0.9240
+5.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±8.2%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
3
2 bearish · 1 mixed
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2
Time to marketPDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.

PDS0301 Updated Nov 11

What to watch

PDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.

Bull case
  • Phase 2 data showed a 71% overall response rate (ORR) in metastatic colorectal cancer patients with liver metastases, a population with very poor prognosis and high unmet need.
  • PDS0301 is a tumor-targeted immunocytokine (IL-12 antibody fusion) designed to concentrate IL-12 at the tumor site, potentially avoiding systemic toxicity while driving anti-tumor immunity.
  • Dr. Patrick Soon-Shiong (NantWorks/Nant Capital) led a $22.3M PIPE financing in September 2026 and joined the Board, signaling deep-pocketed strategic support and potential access to NantWorks' infrastructure.
Bear case
  • PDS0301 is still in early-to-mid stage development (Phase 2), with no guarantee that the promising 71% ORR seen in small Phase 2 cohorts will replicate in larger, more rigorous trials.
  • The company discontinued its Phase 3 PDS0101 program and laid off its pipeline to focus on PDS0301, making it a single-asset company with no revenue and high execution risk.
  • PDSB stock crashed roughly 67% in August 2026 when the strategic refocus was announced, reflecting investor skepticism about abandoning a Phase 3 asset for a Phase 2 candidate.
▼ bearish
Impact
PhasePhase 2 (completed); Phase 3 discontinued)
Time to marketUnknown — the Phase 3 trial has been discontinued and the drug is being shopped for partnership. If partnered, timeline depends on the partner's development plans.

Versamune versamune hpv16 cancer vaccine Updated Oct 23

What to watch

PDS0101 (Versamune) is no longer the company's priority, PDS Biotech discontinued its Phase 3 trial in August 2026 and is seeking a partner. Investors should watch for a licensing deal or partnership announcement, but the stock's near-term catalysts now revolve around PDS0301, not Versamune. The company's severe cash constraints (~$5.6M at Q2 2026) and Nasdaq listing deficiency add urgency to finding a partner.

Bull case
  • PDS0101 (Versamune) showed compelling Phase 2 data: 39.3-month median overall survival when combined with pembrolizumab in first-line HPV16-positive recurrent/metastatic head and neck cancer, far exceeding the ~12-18 month benchmark with standard of care (source: SEC 8-K filing Oct 20, 2026).
  • The strong efficacy data could attract a strategic partner to take over development, potentially generating milestone payments to the company.
  • Analyst consensus remains bullish: 8 Buy/Strong Buy vs 1 Hold, with a mean price target of $5.
Bear case
  • PDS Biotech discontinued internal investment in the PDS0101 Phase 3 VERSATILE-003 trial in August 2026, effectively abandoning the most advanced pipeline program (source: SEC 8-K filing Aug 11, 2026).
  • The company is cash-constrained with ~$5.6M at Q2 2026 and negative working capital of -$5.3M, raising going-concern risk (source: Q2 2026 earnings 8-K filing Aug 13, 2026).
  • A $6M promissory note amendment requires 100% of non-ATM equity proceeds to be swept to the lender, severely limiting the company's ability to retain capital (source: SEC 8-K filing Sep 4, 2026).
▼ bearish
Impact
PhasePreclinical (IND cleared for Phase 1/2)
Time to marketUnknown — the drug is in late-stage preclinical development with an IND cleared for an NCI-led Phase 1/2 trial. Even if the trial begins soon, clinical development typically takes 5+ years for a novel immunotherapy.

PDS0103 Updated Oct 26

What to watch

PDS0103 is a preclinical/IND-stage asset that has been deprioritized by PDS Biotech in favor of PDS0301. The NCI-led Phase 1/2 trial could begin enrollment at any time, but the company has no near-term catalyst for this drug and is actively seeking a partner for the Versamune platform. Watch for partnership announcements or NCI trial initiation as potential value-unlocking events, but the stock's near-term trajectory depends almost entirely on PDS0301 developments.

Bull case
  • PDS0103 targets MUC1, which is overexpressed in multiple solid tumors (ovarian, breast, colorectal, lung), a large addressable market if successful.
  • The IND was cleared by the FDA in March 2025, and the NCI is leading the Phase 1/2 trial under an existing CRADA, a strong validation and cost-efficient development path for PDS Biotech.
  • The Versamune platform has shown encouraging clinical data in other programs (PDS0101 achieved 39.3-month median OS in HPV16-positive head and neck cancer), providing some technology de-risking.
Bear case
  • PDS0103 is only in late-stage preclinical development with no human clinical data yet, a very early, high-risk stage.
  • The company (PDSB) has explicitly deprioritized the entire Versamune platform (including PDS0103) to focus resources on PDS0301, per the August 2026 strategic refocus.
  • PDS Biotech had only $5.6M in cash as of Q2 2026, raising serious questions about how any Versamune program (including PDS0103) gets funded without a partner.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Jan 1, 2026VersamuneAccelerated approval+8.2%+29.0%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Pembrolizumab MonotherapyPhase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaPhase 3Terminated12Aug 25, 2026